Thomas Berg

Professor Dr. Thomas Berg completed his medical training at the Universities of Tübingen, Freiburg and Berlin, Germany. He specialized in internal medicine in 2001 and in Gastroenterology and Hepatology in 2007 at the University Medicine Berlin, and became a lecturer in this subject in 2002. In 2002, Professor Berg took up the position of Associate Director and Professor of Medicine at the Department of Hepatology and Gastroenterology of Charité, Campus Virchow-Clinic, University Medicine in Berlin, where he was Head of the Liver Out-Patient Clinic and the Laboratory for Molecular Hepatitis and Viral Diagnostics. Since December 2009, he has been the Head of the Section of Hepatology at the University Hospital in Leipzig, Germany, and since October 2018 acting Director of the Clinic of Gastroenterology at the University Hospital, Leipzig. His clinical and translational research is focused on chronic viral hepatitis, liver transplantation, hepatocellular carcinoma, genetics in liver disease, and liver failure, and he participated in numerous national and international clinical trials. He is Vice Secretary of the European Associations for the Study of the Liver (EASL), Board member of the EASL International Liver Foundation (EILF) and Co-Editor of the Journal of Hepatology since 2014. He is also member of the American (AASLD), European (EASL), and German (GASL) Associations for the Study of the Liver, The European Society for Organ Transplantation (ESOT), The European Liver and Intestine Transplant Association (ELITA), German Transplantation Society (DTG), Working Group Internal Oncology (AiO), Working Group Gastroenterological Oncology (AGO), German Cancer Society (DKG), German Society of Gastroenterology (DGVS), and the representative of the DGVS in the foundation council of the German liver foundation. He has published more than 350 articles in peer-reviewed journals and more than 100 reviews and textbook contributions. His h-index is 72 (Scopus).

Categorised in:

This post was written by Adrian Somerfield

El-Sayed Manal

Manal El-Sayed, MD, is Professor of Pediatrics at Ain Shams University, Cairo, Egypt, where she trained in medicine and subsequently completed her masters and doctorate in Pediatrics. Since 1990 she has worked in pediatric hematology and oncology teams developing a program for the management of liver disease in children and adolescents with hematological disorders, malignancies and recipients of bone marrow transplantation at Ain Shams University, National Cancer Institute and 57357 Children’s Cancer Hospital. She is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) since 2006 charged with planning and implementing the nationwide program for prevention and management of viral hepatitis. Professor El-Sayed contributed to the establishment of 55 nationwide specialised liver centers connected through a database networking system for management of patients with viral hepatitis, where 350,000 HCV-infected patients received therapy with interferon.
Read more.

Categorised in:

This post was written by SOTO Admin

Newsome Philip N.

Director of the Centre for Liver Research & Professor of Experimental Hepatology, University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital, Birmingham

He graduated from the Medical School at the University of Edinburgh in 1995 and moved to Birmingham in 2007.

He runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD. Professor Newsome has published over 75 research papers in scientific journals as well as many book chapters in the field of Non-Alcoholic Fatty Liver Disease (NAFLD). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapy in NAFLD published in the Lancet, and is also Chief Investigator on a study of Fibroscan in NAFLD. He is editor of a recently published textbook on Liver Transplantation, and chaired the national guidelines for liver transplantation in NAFLD. He sits on the NICE Guideline Development Group for NAFLD.

Categorised in:

This post was written by SOTO Admin

Sironi Andrea

Andrea Sironi is Professor of Banking and Finance at Bocconi University in Milan, where he has been Rector from 2012 to 2016. Since January 2016, he is Chairman of Borsa Italiana SpA and, since October 2016, a member of the Board of Directors of the London Stock Exchange Group. He is currently a member of the Board of Directors of Cassa Depositi e Prestiti SpA and of Cogentech Scarl.
Read more.

Categorised in:

This post was written by SOTO Admin

Thursz Mark

Mark Thursz is Professor of Hepatology at Imperial College where he is head of the Digestive Diseases Division and lead clinician for hepatology at St Mary’s Hospital, London. His clinical interests are in viral hepatitis, alcoholic and fatty liver disease.Prof. Thursz is

Prof. Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial. He is chief investigator on the PROLIFICA programme in West Africa.
Read more.

Categorised in:

This post was written by SOTO Admin

Negro Francesco

Francesco Negro is Professor at the Departments of Medicine and of Pathology and Immunology of the University Hospitals of Geneva, Switzerland. He obtained his Medical Degree in 1982 at the University of Torino, Italy, where he also completed his postgraduate education in Gastroenterology. He was Visiting Scientist and then Assistant Professor at the Georgetown University School of Medicine, Rockville, MD, USA from1986 to 1989, and Guest Researcher at the Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA in 1989. After having spent some time back in Torino, he joined the University Hospitals of Geneva, Switzerland, in 1994. He was appointed Full Professor of the Faculty of Medicine, University of Geneva in 2014. His research interests focus on viral hepatitis, especially on the pathogenesis of metabolic alterations induced by the hepatitis C virus, i.e. steatosis and insulin resistance. More recently, he has participated into numerous collaborative works on epidemiology and public health issues related to viral hepatitis. He has participated in several clinical trials in acute and chronic HCV, authoring or co-authoring ~300 peer-reviewed manuscripts in the field of hepatology. After serving as Educational Councilor within the Governing Board of the European Association for the Study of the Liver (EASL), he is currently Treasurer of EASL for the period 2019-2024. He is also chairing the Swiss Hepatitis C Cohort Study, and is member of the updating panels of the clinical practice guidelines for HCV of the EASL and of the World Health Organisation.

Categorised in:

This post was written by SOTO Admin

Lazarus Jeffrey (Vice-Chairman)

Prof Jeffrey V. Lazarus is an associate research professor at the Barcelona Institute of Global Health (ISGlobal), Hospital Clínic, University of Barcelona and an associate professor at the Faculty of Medicine, University of Barcelona, Spain. His decade-long career as a health systems, HIV and hepatitis expert at WHO’s Regional Office for Europe was followed by three years at the Global Fund to Fight AIDS, Tuberculosis and Malaria, where he led knowledge translation, and then 7 years at the WHO Collaborating Centre on HIV and Viral Hepatitis, in Copenhagen. He is the past director of Health Systems Global and former board chair of the foundation AFEW International.

Read more.

Categorised in:

This post was written by SOTO Admin

Colombo Massimo (Chairman)

Massimo Colombo is Chairman of the EASL International Liver Foundation, Geneva, Switzerland. He is also Head of the Liver Center for Translational Research, IRCCS Humanitas, Milan, Italy. His research interests include the diagnosis and treatment of viral hepatitis, liver transplantation and liver cancer.
Read more.

Categorised in:

This post was written by SOTO Admin

Bruix Jordi

Jordi Bruix is Professor of Medicine at the University of Barcelona and Director of the Barcelona Clinic Liver Cancer (BCLC) Group within the Liver Unit at the Hospital Clinic of Barcelona, Spain. Prof. Bruix has been the principal investigator of studies and clinical trials that have changed practice in the field of hepatocellular carcinoma (HCC),  including  development  of  diagnostic criteria and prognostic models and establishment of chemoembolization, SORAFENIB and REGORAFENIB as EFFECTIVE therapy. He founded the International Liver Cancer Association (ILCA) and was its president from 2006 to 2009.
Read more.

Categorised in:

This post was written by SOTO Admin